Century Therapeutics raises $135M in oversubscribed private placement to fund CNTY-813 T1D program

Century Therapeutics, Inc.

Gross proceeds ~$135M; 117.4M shares/pre-funded warrants + 58.7M warrants at $1.15 per unit.
Led by new investor TCGX; includes RA Capital, Commodore, Deep Track, RTW, Venrock, T1D Fund.
Proceeds fund lead candidate CNTY-813 (beta islet cell for T1D); cash runway extended to Q1 2029.
IND submission for CNTY-813 expected in 2026; initial clinical data anticipated in 2027.
Full exercise of warrants could yield additional ~$153M at $2.60 per share.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Century Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $135.0 million (effective 2026-01-07).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional accredited investors
Value: approximately $135.0 million
Effective: 2026-01-07

Exact text from the filing

On January 7, 2026, Century Therapeutics, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (a) (i) 92,030,595 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, and/or, (ii) pre-funded warrants to purchase 25,360,704 shares of Common Stock (“Pre-Funded Warrants”) and (b) warrants to purchase 58,695,648 shares of Common Stock or Pre-Funded Warrants in lieu thereof (“Common Warrants”, together with the Pre-Funded Warrants, the “Warrants”) at a purchase price of $1.15 per share and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant and a purchase price of $1.1499 per Pre-Funded Warrant and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant (the “Private Placemen

View on SEC.gov

295 material agreements filed in the last 30 days. Browse all material agreements →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-001952

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.